EUVIMEDEUVIMED entdecken
Crossref

Host and Pathogen Pharmacogenetics in Pneumocystis jirovecii Pneumonia After Kidney Transplantation: A Retrospective Cohort and Case–Control Study

Nathalie Henskens iD, Katrien Lagrou iD, Henriette de Loor iD, Lize Cuypers iD, Dirk Kuypers iD

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Nathalie Henskens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Kidney Transplantation, Pneumonia, Pneumocystis, Pneumocystis carinii, Mycophenolic Acid. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kidney transplant recipients are at risk for Pneumocystis jirovecii pneumonia (PJP), particularly under profound immunosuppression. Mycophenolic acid (MPA) is widely used after transplantation and is associated with interindividual variability in exposure and hematologic toxicity. Genetic variation affecting MPA metabolism and pharmacodynamics may contribute to lymphopenia and PJP.

Methods

We performed a matched 1:2 case–control study to assess risk factors for PJP in kidney transplant recipients (1993–2022) using multivariable logistic regression. In addition, a retrospective cohort study restricted to PJP cases evaluated recipient polymorphisms in UGT1A9 , IMPDH2 , and IMPDH1 , and their associations with bone marrow toxicity. P. jirovecii DNA from bronchoalveolar lavage samples was genotyped for IMPDH variants potentially associated with MPA resistance.

Results

Thirty‐nine PJP cases and 78 controls were included. Posttransplant cytomegalovirus infection and lymphopenia were independently associated with PJP. Among PJP cases, carriers of the IMPDH1 rs2278294 variant had a significantly higher incidence of lymphopenia, independent of MPA dose. P. jirovecii genotyping was obtained for 24 patients. The IMPDH Ala261Thr variant was detected in 16.7% and the Ala261Ser variant in 22.2% of MPA‐treated patients, which is substantially lower than previously reported.

Conclusions

In kidney transplant recipients with PJP, host genetic variation in IMPDH1, rather than polymorphisms affecting MPA metabolism, appears to be associated with lymphopenia and infection susceptibility. In contrast to prior reports, no clear enrichment of MPA resistance‐associated P. jirovecii IMPDH variants was observed. These findings underscore the complexity of host–pathogen interactions under immunosuppressive therapy and highlight the need for larger, well‐controlled studies integrating pharmacogenetics and microbial genomics. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationPneumonia, PneumocystisPneumocystis cariniiMycophenolic AcidImmunosuppressive AgentsHumansRetrospective StudiesFemaleCase-Control StudiesIMP DehydrogenaseMaleMiddle AgedAdultRisk FactorsPharmacogeneticsLymphopeniaGlucuronosyltransferase

Stichwörter der Autor:innen

IMPDHPneumocystis jirovecii pneumoniaUGT1A9kidney transplantationmycophenolic acid

Substanzen

Mycophenolic AcidIMP DehydrogenaseImmunosuppressive AgentsIMPDH1 protein, humanIMPDH2 protein, humanGlucuronosyltransferase

Autor:innen und Institutionen

  • Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Department of Laboratory Medicine, National Reference Center for Mycoses, UZ Leuven, Leuven, Belgium.
  • Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium.

ORCID-Profile: Nathalie Henskens, Katrien Lagrou, Henriette de Loor, Lize Cuypers, Dirk Kuypers

Zitieren

APA

Henskens, N., Lagrou, K., de Loor, H., Cuypers, L., & Kuypers, D. (2026). Host and Pathogen Pharmacogenetics in Pneumocystis jirovecii Pneumonia After Kidney Transplantation: A Retrospective Cohort and Case–Control Study. Transplant Infectious Disease. https://doi.org/10.1111/tid.70257

Vancouver

Henskens N, Lagrou K, de Loor H, Cuypers L, Kuypers D. Host and Pathogen Pharmacogenetics in Pneumocystis jirovecii Pneumonia After Kidney Transplantation: A Retrospective Cohort and Case–Control Study. Transplant Infectious Disease. 2026. doi:10.1111/tid.70257

BibTeX
@article{Henskens2026,
  author = {Henskens, Nathalie and Lagrou, Katrien and de Loor, Henriette and Cuypers, Lize and Kuypers, Dirk},
  title = {Host and Pathogen Pharmacogenetics in Pneumocystis jirovecii Pneumonia After Kidney Transplantation: A Retrospective Cohort and Case–Control Study},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70257}
}
Kostenlos starten →